COVID-19 infection with an increased risk of progressing to severe COVID-19

Active Ingredient: Remdesivir

Indication for Remdesivir

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Remdesivir is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

For this indication, competent medicine agencies globally authorize below treatments:

200 mg single loading dose on Day 1 and thereafter 100 mg once daily for 3 days

For:

Dosage regimens

Intravenous, 200 milligrams remdesivir, one dose, over the duration of 1 day. Afterwards, intravenous, 100 milligrams remdesivir, once daily, over the duration of 2 days.

Detailed description

Table 1. Recommended dose in adults and paediatric patients:

 Given by intravenous infusion
Adults
Day 1
(single loading dose) 		200 mg
Day 2 and onwards
(once daily) 		100 mg

Table 2. Treatment duration:

 Adults
Patients who do not
require supplemental
oxygen and are at
increased risk for
progressing to severe
COVID-19		Daily for 3 days,
starting as soon as
possible after
diagnosis of
COVID-19 and
within 7 days of
the onset of
symptoms.

For patients weighting ≥40 kg 200 mg single loading dose on Day 1 and thereafter 100 mg once daily for 2 days

For:

Dosage regimens

In case that patient weight is ≥ 40 kg, intravenous, 200 milligrams remdesivir, one dose, over the duration of 1 day. Afterwards, in case that patient weight is ≥ 40 kg, intravenous, 100 milligrams remdesivir, once daily, over the duration of 2 days.

Detailed description

 Given by intravenous infusion
Adults Paediatric patients
(weighing at least
40 kg) 		Paediatric patients at least
4 weeks old (weighing at
least 3 kg but less than
40 kg)
Day 1
(single loading dose) 		200 mg 200 mg 5 mg/kg
Day 2 and onwards
(once daily) 		100 mg 100 mg 2.5 mg/kg

Table 2. Treatment duration:

 Paediatric patients
(weighing at least
40 kg)
Patients who do not
require supplemental
oxygen and are at
increased risk for
progressing to severe
COVID-19		Daily for 3 days,
starting as soon as
possible after diagnosis
of COVID-19 and
within 7 days of the
onset of symptoms.

Active ingredient

Remdesivir

Remdesivir is an adenosine nucleotide prodrug that is metabolized within host cells to form the pharmacologically active nucleoside triphosphate metabolite. Remdesivir triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. As an additional mechanism, remdesivir triphosphate can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur in the presence of higher nucleotide concentrations.

Read more about Remdesivir

Related medicines

Summary of Product Characteristics (SPC) 2023: VEKLURY Powder for concentrate for solution for infusion

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈